51
Participants
Start Date
August 9, 2018
Primary Completion Date
April 1, 2026
Study Completion Date
February 19, 2029
Sarilumab SAR153191 (REGN88)
"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
RECRUITING
Investigational Site Number : 1000001, Plovdiv
RECRUITING
Investigational Site Number : 2760064, Berlin
RECRUITING
Investigational Site Number : 2760065, Berlin
RECRUITING
Investigational Site Number : 3800051, Genoa
RECRUITING
Investigational Site Number : 3800054, Milan
RECRUITING
Investigational Site Number : 2760062, Hamburg
RECRUITING
Investigational Site Number : 7240053, Madrid
RECRUITING
Investigational Site Number : 7240056, Madrid
RECRUITING
Investigational Site Number : 2500042, Montpellier
RECRUITING
Investigational Site Number : 7240051, Valencia
COMPLETED
Investigational Site Number : 2760063, Sendenhorst
RECRUITING
Investigational Site Number : 2760060, Sankt Augustin
RECRUITING
Investigational Site Number : 2500041, Bron
RECRUITING
Investigational Site Number : 2500040, Paris
COMPLETED
Investigational Site Number : 6430001, Moscow
COMPLETED
Investigational Site Number : 6430062, Moscow
COMPLETED
Investigational Site Number : 6430063, Moscow
COMPLETED
Investigational Site Number : 6430065, Ufa
RECRUITING
Investigational Site Number : 0320004, San Miguel de Tucumán
RECRUITING
Investigational Site Number : 1240110, Calgary
RECRUITING
Investigational Site Number : 1240112, Montreal
RECRUITING
Investigational Site Number : 2460040, Helsinki
RECRUITING
Investigational Site Number : 3720001, Dublin
RECRUITING
Investigational Site Number : 3800052, Rome
RECRUITING
Investigational Site Number : 7240055, Barcelona
RECRUITING
Investigational Site Number : 7240050, Esplugues de Llobregat
COMPLETED
Investigational Site Number : 8260031, London
RECRUITING
Investigational Site Number : 8260034, Leeds
COMPLETED
Investigational Site Number : 8260033, Liverpool
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY